Arrowg+ard Blue Advance™ PICC
Peripherally Inserted Central Catheters (PICC)
Peripherally Inserted Central Catheters (PICC)
At Teleflex, we believe no one should suffer from the consequences of preventable vascular access-related complications. That’s why we’re partnering with healthcare facilities to offer a comprehensive, consultative approach to vascular access.
The Arrowg+ard Blue Advance™ PICC is designed to protect both internal and external catheter surfaces with chlorhexidine, reducing the risk of these catheter-related complications:4,5
Intraluminal thrombotic occlusion5,6
Microbial colonization4
Phlebitis7
Intimal hyperplasia7
Demonstrated a 92% reduction of fibrin sheath accumulation on catheter surfaces at 31 days5
99.99% colonization reduction in gram-positive and gram-negative bacterial and fungal pathogens for at least 30 days4
Reduced thrombotic intraluminal occlusion as evidenced by 51% reduction in flush pressure to clear thrombus6
Get in touch with our product specialist/ sales representative and learn how this device can elevate your services.
*US based data
Rx Only.
Not all products shown on the website may be approved in all regulatory jurisdictions. Consult with your local Teleflex representative for details.
Contraindications:
Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ PICC is contraindicated in the following areas:
No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
1. Husch M, et al. Qual Saf Health Care. 2005; 2. Medicare.gov. Hospital-Acquired Condition Reduction Program. https://www.medicare.gov/hospitalcompare/HAC-reduction-program.html. Accessed Aug 23 2023. The Hospital Pay-for-Performance File How P4P may impact your hospital partners in 2017. Retrieved 23 Aug 2023, from https://www.advisory.com/research/health-care-industry-committee/members/resources/2014/p4p-impact-file; 3. Centers for Medicare and Medicaid Services. Fiscal Year (FY) 2016 Results for the CMS Hospital-Acquired Conditions (HAC) Reduction Program. https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2015-Fact-sheets-items/2015-12-10-2.html. Accessed 23 Aug, 2023; 4. In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained; 5. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus: AVAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained; 6. As compared to uncoated PICCs, in vitro model measuring flush pressure post exposure to bovine blood: AVER-006376. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained; 7. As compared to uncoated PICCs, intravascular ovine model: VAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained; 8. Nifong TP and McDevitt TJ. Chest 2011; 9. Grove JR, Pevec WC. Jvir. 2000; 10. Trerotola, S, et al. Radiology 2010; 11. Rosenbauer KA, Herzer JA. Scan Electron Microsc. 1981; 12. Collins JL, Lutz RJ. Heart & Lung. 1991
Teleflex, Teleflex logo, AC3 Optimus, Arrow, Arrowg+ard, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, and EZ-IO are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. All other trademarks or registered trademarks appearing on the web site are the property of their respective owners.
